熱門資訊> 正文

Compass Therapeutics GAAP每股收益为-0.10美元在线

2026-05-05 19:35

Compass Therapeutics, Inc.(CMPX) 0

Compass Therapeutics press release (CMPX): Q1 GAAP EPS of -$0.10 in-line.
As of March 31, 2026, cash and marketable securities were $195 million as compared to $209 million as of December 31, 2025, a decrease of $14 million, with an anticipated cash runway into 2028. During the first quarter of 2026, $18 million of net cash was used in operating activities, and this was partially offset by proceeds from exercise of common stock of $4 million.

More on Compass Therapeutics

Compass Therapeutics, Inc. (CMPX) Discusses Positive Secondary Endpoint Results From COMPANION-002 Study in Advanced Biliary Tract Cancer Transcript
Compass Therapeutics: Potential Here, But Patience Required
Compass Therapeutics plunges on tovecimig missing overall survival endpoint
Compass Therapeutics GAAP EPS of -$0.09
Seeking Alpha’s Quant Rating on Compass Therapeutics

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。